APIM-peptide targeting PCNA improves the efficacy of docetaxel treatment in the TRAMP mouse model of prostate cancer

Docetaxel is the chemotherapeutic choice for metastatic hormone-refractory prostate cancer, however, it only marginally improves the survival rate. The purpose of the present study was to examine if a peptide targeting the cellular scaffold protein PCNA could improve docetaxel’s efficacy. We found t...

Descripción completa

Detalles Bibliográficos
Autores principales: Søgaard, Caroline K., Moestue, Siver A., Rye, Morten B., Kim, Jana, Nepal, Anala, Liabakk, Nina-Beate, Bachke, Siri, Bathen, Tone F., Otterlei, Marit, Hill, Deborah K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837745/
https://www.ncbi.nlm.nih.gov/pubmed/29545934
http://dx.doi.org/10.18632/oncotarget.24357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837745/
https://www.ncbi.nlm.nih.gov/pubmed/29545934
http://dx.doi.org/10.18632/oncotarget.24357

Ejemplares similares